Two oral GLP-1s have now received FDA approval: Novo Nordisks WEGOVY pill (December 2025) and Eli Lillys FOUNDAYO (April 2026)
Lo que sabemos y, sobre todo, lo que NO sabemos: En animales: El perfil de seguridad parece aceptable a corto plazo
Eluted fractions consisting of receptor and G-protein complex were pooled and concentrated to 2-4mg/mL
Whilst individual tolerance varies considerably, clinical trial data suggest that dulaglutide and liraglutide may cause slightly fewer gastrointestinal symptoms than higher-dose semaglutide or tirzepatide
Liver Health: Methionine, inositol, and choline are essential for liver health and function
You may recall another of our At a glance factsheets , also by Steve Bain, outlining the evidence regarding diabetic retinopathy in users of GLP-1 RAs, with recommendations on safe use